DRAGdb: Drug Resistance Associated Genes
Number of mutation entries of gyrA is 428
PROVEAN score threshold is -2.5. Variants with score = or < -2.5 are considered deleterious.Variants with score > -2.5 are considered neutral.
| ORGANISM_NAME | GENE_NAME | ENSEMBL_ID | DRUG_NAME | NUCLEOTIDE_POSITION | NUCLEOTIDE_MUTATION | AMINOACID_POSITION | AMINOACID_MUTATION | PROVEAN_SCORE | SAMPLE_LOCATION |
|---|---|---|---|---|---|---|---|---|---|
| Citrobacter freundii | gyrA | AB07_1363 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | ACC - ATC | 83 | Thr - Ile | -3.545 | Argentina |
| Salmonella enterica Serovar Typhimurium var 5 | gyrA | AEV03_14785 | Quinolone | 259 | G - A | 87 | Asp - Asn | -4.56 | NA |
| Salmonella enterica Serovar Typhimurium var 5 | gyrA | AEV03_14785 | Quinolone | 2590 | C - T | 864 | Pro - Ser | -0.172 | NA |
| Salmonella enterica Serovar Dublin | gyrA | AEW76_09460 | Quinolone | 259 | G - T | 87 | Asp - Tyr | -8.274 | NA |
| Salmonella enterica Serovar Dublin | gyrA | AEW76_09460 | Quinolone | 248 | C - T | 83 | Ser - Phe | -4.548 | NA |
| Arcobacter butzleri | gyrA | AF80_03480 | Quinolone | 254 | C - T | 85 | Thr - Ile | -3.624 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 299 | A - G | 100 | Asp - Gly | -6.953 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 298 | G - C | 100 | Asp - His | -6.953 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 295 - 297 | NA | 99 | Gly - Asp | -6.948 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 313 | G - C | 105 | Asp - His | -6.88 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 314 | A - G | 105 | Asp - Gly | -6.834 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 302 | C - G | 101 | Ser - Trp | -5.621 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 298 | G - A | 100 | Asp - Asn | -4.967 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 302 | C - T | 101 | Ser - Leu | -4.612 | NA |
| Cutibacterium acnes | gyrA | AK828_05630 | Fluoroquinolone (Levofloxacin) | 304 | G - C | 102 | Ala - Pro | -3.968 | NA |
| Acinetobacter baumannii | gyrA | AO727_01490 | Quinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.408 | NA |
| Acinetobacter baumannii | gyrA | AO727_01490 | Quinolone | 260 | A - G | 87 | Glu - Gly | -3.412 | NA |
| Aeromonas veronii | gyrA | AO744_12715 | Fluoroquinolone (Ciprofloxacin / Levofloxacin / Norfloxacin) | 248 | AGC - ATC | 83 | Ser - Ile | NA | Sichuan Province in China |
| Neisseria gonorrhoeae | gyrA | AW44_08030 | Fluoroquinolone (Ciprofloxacin) | 272 | C - T | 91 | Ser - Phe | -4.456 | India |
| Staphylococcus aureus | gyrA | AZ30_00030 | Fluoroquinolone | 251 | T - C | 84 | Leu - Ser | 4.659 | South Texas in United States |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 259 | G - T | 87 | Asp - Tyr | -8.258 | Argentina |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid | 259 | G - T | 87 | Asp - Tyr | -8.258 | Taiwan |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 259 | G - T | 87 | Asp - Tyr | -8.258 | Korea |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 260 | A - G | 87 | Asp - Gly | -6.486 | Argentina |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin) | 260 | A - G | 87 | Asp - Gly | -6.486 | NA |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) / Triclosan | 260 | A - G | 87 | Asp - Gly | -6.486 | NA |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid | 260 | NA | 87 | Asp - Gly | -6.486 | Taiwan |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 260 | A - G | 87 | Asp - Gly | -6.486 | Korea |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin) | 259 | G - C | 87 | Asp - His | -6.331 | NA |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 259 | G - C | 87 | Asp - His | -6.331 | Korea |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 149 | A - G | 50 | Tyr - Cys | -5.587 | Mangalore in India |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) / Triclosan | 248 | C - T | 83 | Ser - Phe | -4.559 | NA |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 259 | G - A | 87 | Asp - Asn | -4.544 | Argentina |
| Escherichia coli | gyrA | b2231 | Quinolone | 259 | G - A | 87 | Asp - Asn | -4.544 | China |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 259 | G - A | 87 | Asp - Asn | -4.544 | Mangalore in India |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.544 | NA |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid | 259 | G - A | 87 | Asp - Asn | -4.544 | Taiwan |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 259 | G - A | 87 | Asp - Asn | -4.544 | Korea |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Argentina |
| Escherichia coli | gyrA | b2231 | Quinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | China |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Mangalore in India |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin) | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | NA |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin) | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | NA |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Taiwan |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Korea |
| Escherichia coli | gyrA | b2231 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 247 | TCG - GCG | 83 | Ser - Ala | -2.112 | Argentina |
| Escherichia coli | gyrA | b2231 | Nalidixic Acid | 247 | TCG - GCG | 83 | Ser - Ala | -2.112 | Taiwan |
| Clostridium difficile | gyrA | BG47_01785 | Quinolone | 245 | C - T | 82 | Thr - Ile | -2.326 | Taiwan |
| Staphylococcus aureus | gyrA | CH52_05420 | Fluoroquinolone (Ciprofloxacin) | 316 - 318 | NA | 106 | Gly - Asp | -6.748 | Hatay in turkey |
| Staphylococcus aureus | gyrA | CH52_05420 | Fluoroquinolone (Ciprofloxacin) | 251 | TCA - TTA | 84 | Ser - Leu | -4.66 | Hatay in turkey |
| Staphylococcus aureus | gyrA | CH52_05420 | Quinolone | 251 | TCA - TTA | 84 | Ser - Leu | -4.66 | NA |
| Staphylococcus aureus | gyrA | CH52_05420 | Fluoroquinolone | 251 | TCA - TTA | 84 | Ser - Leu | -4.66 | NA |
| Staphylococcus aureus | gyrA | CH52_05420 | Quinolone | 262 | GAA - AAA | 88 | Glu - Lys | -3.252 | NA |
| Staphylococcus aureus | gyrA | CH52_05420 | Quinolone | 253 | TCT - CCT | 85 | Ser - Pro | -2.752 | NA |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Enrofloxacin) | 608 | AAT - AGT | 203 | Asn - Ser | -3.919 | Thailand |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone | 608 | AAT - AGT | 203 | Asn - Ser | -3.919 | United States |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 310 | C - T | 104 | Pro - Ser | -3.377 | NA |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Enrofloxacin) | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | Thailand |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | China |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | United States |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | NA |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | Lima in Peru |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 257 | ACA - ATA | 86 | Thr - Ile | -3.321 | NA |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 364 | GCG - TCG | 122 | Ala - Ser | -2.89 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 408 | GAG - GAT | 136 | Glu - Asp | -2.718 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Enrofloxacin) | 64 | AGT - GGT | 22 | Ser - Gly | -2.009 | Thailand |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone | 64 | AGT - GGT | 22 | Ser - Gly | -2.009 | United States |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 64 | AGT - GGT | 22 | Ser - Gly | -2.009 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Nalidixic Acid | 256 | A - G | 86 | Thr - Ala | -1.944 | Lima in Peru |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 445 | GTT - ATT | 149 | Val - Ile | -0.305 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 63 | AAA - AAG | 21 | Lys - Lys | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 72 | TAT - TAC | 24 | Tyr - Tyr | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 84 | TCT - TCC | 28 | Ser - Ser | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 117 | GAC - GAT | 39 | Asp - Asp | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 177 | GAG - GAA | 59 | Glu - Glu | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 231-232 | GGT - GCC | 78 | Gly - Gly | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 243 | CAC - CAT | 81 | His - His | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 330 | GGC - GGT | 110 | Gly - Gly | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 357 | AGT - AGC | 119 | Ser - Ser | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 360 | GCC - GCT | 120 | Ala - Ala | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 456 | TAT - TAC | 152 | Tyr - Tyr | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 471 | AGC - AGT | 157 | Ser - Ser | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 483 | GTT - GTC | 161 | Val - Val | 0 | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Enrofloxacin) | 617 | GCA - GTA | 206 | Ala - Val | 0.83 | Thailand |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 115 | GCA - TCA | 39 | Ala - Ser | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 146 | AGA - AAA | 48 | Arg - Lys | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 189 | GAA - GAG | 63 | Glu - Glu | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 207 | CAG - CAA | 69 | Gln - Gln | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 253 | ACA - GCA | 85 | Thr - Ala | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 291 | AAG - AAA | 97 | Lys - Lys | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 351 | GTG - GTC | 117 | Val - Val | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 354 | ATA - ATC | 118 | Ile - Ile | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 411 | AGC - AGT | 137 | Ser - Ser | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 435 | AGC - AGT | 145 | Ser - Ser | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone (Ciprofloxacin) | 447 | TTC - TTT | 149 | Phe - Phe | NA | Lithuania |
| Campylobacter jejuni | gyrA | CJJ5050_08730 | Fluoroquinolone | 854 | G - A | 285 | Arg - Lys | NA | United States |
| Haemophilus influenzae | gyrA | CK45_03660 | Fluoroquinolone (Tosufloxacin / Levofloxacin) | 251 | C - T | 84 | Ser - Leu | -4.057 | Tokyo in Japan |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Nalidixic Acid | 259 | G - T | 87 | Asp - Tyr | -8.274 | Brazil |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 259 | G - T | 87 | Asp - Tyr | -8.274 | Thailand |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin) | 260 | A - G | 87 | Asp - Gly | -6.468 | NA |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 260 | A - G | 87 | Asp - Gly | -6.468 | Thailand |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 248 | C - A | 83 | Ser - Tyr | -4.565 | Thailand |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Nalidixic Acid | 259 | G - A | 87 | Asp - Asn | -4.56 | Brazil |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 259 | G - A | 87 | Asp - Asn | -4.56 | Thailand |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Nalidixic Acid | 248 | C - T | 83 | Ser - Phe | -4.548 | Brazil |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 248 | C - T | 83 | Ser - Phe | -4.548 | Thailand |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 248 | C - T | 83 | Ser - Phe | -4.548 | Thailand |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Nalidixic Acid | 289 | T - C | 97 | Ser - Pro | -4.509 | Brazil |
| Salmonella enterica Serovar Enteritidis | gyrA | CS37_11380 | Fluoroquinolone (Ciprofloxacin / Norfloxacin) / Nalidixic Acid | 248 | AGC - ATC | 83 | Ser - Ile | -4.182 | Thailand |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Nalidixic Acid | 259 | G - T | 87 | Asp - Tyr | -8.274 | NA |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Fluoroquinolone (Ciprofloxacin) | 259 | G - T | 87 | Asp - Tyr | -8.274 | Shanghai in China |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) / Triclosan | 260 | A - G | 87 | Asp - Gly | -6.468 | NA |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Fluoroquinolone (Marbofloxacin) | 259 | G - C | 87 | Asp - His | -6.38 | NA |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.56 | NA |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.56 | Shanghai in China |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Fluoroquinolone (Marbofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | NA |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) / Triclosan | 248 | C - T | 83 | Ser - Phe | -4.548 | NA |
| Salmonella enterica Serovar Typhimurium | gyrA | CY43_12185 | Fluoroquinolone (Ciprofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | Shanghai in China |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 98 | C - A | 33 | Pro - His | -8.38 | Colombia |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - G | 81 | Ser - Trp | -6.553 | Netherlands |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin) | 254 | A - G | 85 | Glu - Gly | -5.862 | Aachen in Germany |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin) | 242 | C - A | 81 | Ser - Tyr | -5.588 | Aachen in Germany |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - A | 81 | Ser - Tyr | -5.588 | Spain |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - A | 81 | Ser - Tyr | -5.588 | Taiwan |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Sitafloxacin / Tosufloxacin / Garenoxacin) | 242 | C - A | 81 | Ser - Tyr | -5.588 | Tohoku area in Japan |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin) | 242 | C - T | 81 | Ser - Phe | -5.583 | Aachen in Germany |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - T | 81 | Ser - Phe | -5.583 | Colombia |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - T | 81 | Ser - Phe | -5.583 | Spain |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - T | 81 | Ser - Phe | -5.583 | Sweden |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 242 | C - T | 81 | Ser - Phe | -5.583 | Taiwan |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Sitafloxacin / Tosufloxacin / Garenoxacin) | 242 | C - T | 81 | Ser - Phe | -5.583 | Tohoku area in Japan |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin) | 254 | A - C | 85 | Glu - Ala | -5.175 | Aachen in Germany |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin) | 253 | G - A | 85 | Glu - Lys | -3.517 | Aachen in Germany |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 253 | G - A | 85 | Glu - Lys | -3.517 | Colombia |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 253 | G - A | 85 | Glu - Lys | -3.517 | Spain |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Sitafloxacin / Tosufloxacin / Garenoxacin) | 253 | G - A | 85 | Glu - Lys | -3.517 | Tohoku area in Japan |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 340 - 342 | NA | 114 | Ser - Gly | 2.033 | Netherlands |
| Streptococcus pneumoniae | gyrA | DB40_02095 | Fluoroquinolone (Levofloxacin / Moxifloxacin) | 340 - 342 | NA | 114 | Ser - Gly | 2.033 | Spain |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 239 | CAT - CCT | 80 | His - Pro | -9.651 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 260 | GAC - GTC | 87 | Asp - Val | -8.27 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 259 | GAC - TAC | 87 | Asp - Tyr | -8.258 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 260 | GAC - GCC | 87 | Asp - Ala | -7.306 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 260 | GAC - GGC | 87 | Asp - Gly | -6.486 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 171 | AAT - AAA | 57 | Asn - Lys | -5.764 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 259 | GAC - AAC | 87 | Asp - Asn | -4.544 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Jiangsu Province of China |
| Shigella flexneri | gyrA | DP20_4113 | Nalidixic Acid / Fluoroquinolone (Norfloxacin) | 631 | CAC - TAC | 211 | His - Tyr | 1.544 | Jiangsu Province of China |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone (Ciprofloxacin) | 259 | GAC - TAC | 87 | Asp - Tyr | -8.411 | Northern of Iran |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone | 259 | GAC - AAC | 87 | Asp - Asn | -4.647 | Japan |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone | 248 | ACC - ATC | 83 | Thr - Ile | -3.72 | Australia |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone | 248 | ACC - ATC | 83 | Thr - Ile | -3.72 | Japan |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone (Ciprofloxacin) | 248 | ACC - ATC | 83 | Thr - Ile | -3.72 | Northern of Iran |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone (Ciprofloxacin) | 248 | ACC - ATC | 83 | Thr - Ile | -3.72 | Tunisia |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone | 248 | ACC - ATC | 83 | Thr - Ile | -3.72 | Vietnam |
| Pseudomonas aeruginosa | gyrA | DQ20_03635 | Fluoroquinolone | 398 | ACG - ATG | 133 | Thr - Met | NA | Vietnam |
| Francisella novicida | gyrA | DR83_750 | Fluoroquinolone | 1573 - 1575 | NA | 525 | Ser - Deletion | -9.364 | NA |
| Francisella novicida | gyrA | DR83_750 | Fluoroquinolone | 1570 - 1572 | NA | 524 | Glu - Deletion | -8.674 | NA |
| Francisella novicida | gyrA | DR83_750 | Fluoroquinolone | 259 | G - T | 87 | Asp - Tyr | -8.465 | NA |
| Francisella novicida | gyrA | DR83_750 | Fluoroquinolone | 128 | C - A | 43 | Pro - His | -8.378 | NA |
| Francisella novicida | gyrA | DR83_750 | Fluoroquinolone | 260 | A - G | 87 | Asp - Gly | -6.587 | NA |
| Francisella tularensis | gyrA | DR85_1299 | Fluoroquinolone | 259 | G - T | 87 | Asp - Tyr | -8.615 | NA |
| Francisella tularensis | gyrA | DR85_1299 | Fluoroquinolone | 248 | ACC - ATC | 83 | Thr - Ile | -4.003 | NA |
| Francisella tularensis | gyrA | DR85_1299 | Fluoroquinolone | 248 | C - A | 83 | Thr - Lys | -3.172 | NA |
| Moraxella catarrhalis | gyrA | DR90_841 | Fluoroquinolone (Levofloxacin / Sitafloxacin / Tosufloxacin / Garenoxacin) | 239 | C - T | 80 | Thr - Ile | -3.769 | Tohoku area in Japan |
| Providencia stuartii | gyrA | DR96_3611 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | AGC - ATC | 83 | Ser - Ile | -4.06 | Argentina |
| Providencia stuartii | gyrA | DR96_3611 | Fluoroquinolone | 248 | AGC - ATC | 83 | Ser - Ile | -4.06 | southern Taiwan |
| Providencia stuartii | gyrA | DR96_3611 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 247 - 249 | NA | 83 | Ser - Arg | -3.596 | Argentina |
| Enterococcus faecalis | gyrA | EE55_10450 | Fluoroquinolone | 260 | A - G | 87 | Glu - Gly | -5.973 | Gyeonggi Province in Korea |
| Enterococcus faecalis | gyrA | EE55_10450 | Fluoroquinolone | 248 | C - A | 83 | Ser - Tyr | -5.566 | Gyeonggi Province in Korea |
| Enterococcus faecalis | gyrA | EE55_10450 | Fluoroquinolone | 248 | C - T | 83 | Ser - Phe | -5.561 | Gyeonggi Province in Korea |
| Enterococcus faecalis | gyrA | EE55_10450 | Fluoroquinolone | 248 | AGC - ATC | 83 | Ser - Ile | -5.514 | Gyeonggi Province in Korea |
| Enterococcus faecalis | gyrA | EE55_10450 | Fluoroquinolone | 247 - 249 | NA | 83 | Ser - Arg | -4.642 | Gyeonggi Province in Korea |
| Staphylococcus epidermidis | gyrA | EL82_09050 | Fluoroquinolone | 251 | C - A | 84 | Ser - Tyr | -5.024 | NA |
| Staphylococcus epidermidis | gyrA | EL82_09050 | Fluoroquinolone | 251 | C - T | 84 | Ser - Phe | -4.996 | NA |
| Shigella sonnei | gyrA | ERS127223_04184 | Fluoroquinolone | 260 | GAC - GCC | 87 | Asp - Gly | -6.486 | Jiangsu Province of China |
| Shigella sonnei | gyrA | ERS127223_04184 | Fluoroquinolone | 259 | GAC - AAC | 87 | Asp - Asn | -4.544 | Jiangsu Province of China |
| Shigella sonnei | gyrA | ERS127223_04184 | Fluoroquinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Jiangsu Province of China |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Fluoroquinolone (Ciprofloxacin) | 260 | A - G | 87 | Asp - Gly | -6.468 | Kolkata in India |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.56 | India |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.56 | Kolkata in India |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.56 | NA |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | India |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Fluoroquinolone (Ciprofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | Kolkata in India |
| Salmonella enterica Serovar Typhi | gyrA | ERS326222_03263 | Fluoroquinolone (Ciprofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | NA |
| Shigella flexneri 2a | gyrA | ERS574920_03941 | Fluoroquinolone | 259 | G - T | 87 | Asp - Tyr | -8.258 | Northwest China |
| Shigella flexneri 2a | gyrA | ERS574920_03941 | Fluoroquinolone | 259 | G - A | 87 | Asp - Asn | -4.544 | Northwest China |
| Shigella flexneri 2a | gyrA | ERS574920_03941 | Fluoroquinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.203 | Northwest China |
| Actinotignum schaalii | gyrA | FB03_06620 | Fluoroquinolone (Ciprofloxacin) | 247 | TCG - GCG | 83 | Ser - Ala | NA | NA |
| Propionibacterium acnes | gyrA | FB41_0385 | Fluoroquinolone | 314 | A - G | 105 | Asp - Gly | -6.834 | Japan |
| Propionibacterium acnes | gyrA | FB41_0385 | Fluoroquinolone | 302 | C - G | 101 | Ser - Trp | -5.621 | Japan |
| Propionibacterium acnes | gyrA | FB41_0385 | Fluoroquinolone | 302 | C - T | 101 | Ser - Leu | -4.612 | Japan |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 224 | G - T | 75 | Gly - Val | -8.823 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 562 | C - T | 188 | Pro - Ser | -7.747 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 296 | A - T | 99 | Asp - Val | -7.389 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - T | 91 | Asp - Tyr | -7.358 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 271 | G - T | 91 | Asp - Tyr | -7.358 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - T | 91 | Asp - Tyr | -7.358 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - T | 91 | Asp - Tyr | -7.358 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 293 | A - T | 98 | Gln - Leu | -6.862 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 445 | T - G | 149 | Phe - Val | -6.445 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 272 | A - G | 91 | Asp - Gly | -5.952 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 272 | A - G | 91 | Asp - Gly | -5.952 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 272 | A - G | 91 | Asp - Gly | -5.952 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 272 | A - G | 91 | Asp - Gly | -5.952 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 271 | G - C | 91 | Asp - His | -5.547 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 173 | A - G | 58 | Glu - Gly | -4.962 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 589 - 591 | NA | 197 | Ala - Phe | -4.635 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 262 | G - C | 88 | Ala - Pro | -4.55 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 262 | G - C | 88 | Ala - Pro | -4.55 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 290 | C - T | 97 | Ala - Val | -3.915 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - A | 91 | Asp - Asn | -3.901 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 271 | G - A | 91 | Asp - Asn | -3.901 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - A | 91 | Asp - Asn | -3.901 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - A | 91 | Asp - Asn | -3.901 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 271 | G - A | 91 | Asp - Asn | -3.901 | Venezuela |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 433 | G - A | 145 | Asp - Asn | -3.359 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 485 | T - C | 162 | Ile - Thr | -3.229 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 580 | A - T | 194 | Ile - Phe | -3.21 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 385 | G - A | 129 | Ala - Thr | -2.994 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 579 | A - T | 193 | Glu - Asp | -2.9 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 389 | G - A | 130 | Arg - Lys | -2.06 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 259 | A - T | 87 | Asn - Tyr | -1.909 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 481 | G - A | 161 | Asp - Asn | -1.475 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 260 | A - T | 87 | Asn - Ile | -1.116 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 260 | A - T | 87 | Asn - Ile | -1.116 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 260 | A - T | 87 | Asn - Ile | -1.116 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 260 | A - T | 87 | Asn - Ile | -1.116 | Venezuela |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 261 | NA | 87 | Asn - Lys | -0.82 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 261 | C - A | 87 | Asn - Lys | -0.82 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 261 | C - G | 87 | Asn - Lys | -0.82 | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 261 | NA | 87 | Asn - Lys | -0.82 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 261 | NA | 87 | Asn - Lys | -0.82 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 187 | T - C | 63 | Ser - Pro | -0.772 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 419 | G - A | 140 | Arg - Lys | -0.57 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 574 | G - A | 192 | Asp - Asn | -0.116 | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 259 - 261 | NA | 87 | Asn - Ala | -0.011 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 514 | G - A | 172 | Val - Ile | 0.232 | Kathmandu in Nepal |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 401 | C - T | 134 | Ala - Val | 2.099 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 260 | A - C | 87 | Asn - Thr | 2.101 | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 260 | A - C | 87 | Asn - Thr | 2.101 | Venezuela |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 100 | G - A | 34 | Asp - Asn | NA | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 100 | G - T | 34 | Asp - Tyr | NA | Indonesia |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone | 260 | C - T | 87 | Thr - Ile | NA | France |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 1303 | G - A | 435 | Asp - Asn | NA | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 1435 - 1437 | NA | 479 | Ser - Gly | NA | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 1435 - 1437 | NA | 479 | Ser - Gly | NA | Dominican Republic |
| Helicobacter pylori | gyrA | HP2RS_00240 / HP2RS_00245 | Fluoroquinolone (Levofloxacin) | 1435 - 1437 | NA | 479 | Ser - Gly | NA | Indonesia |
| Bacteroides fragilis | gyrA | IB64_02590 | Fluoroquinolone | 245 | C - T | 82 | Ser - Phe | -5.083 | Hungary |
| Serratia marcescens | gyrA | IY40_03600 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 247 - 249 | NA | 83 | Ser - Arg | -3.597 | Argentina |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone | 247 - 249 | NA | 83 | Ser - Arg | NA | Gyeonggi Province in Korea |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone | 248 | AGC - ATC | 83 | Ser - Ile | NA | Gyeonggi Province in Korea |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone | 248 | C - T | 83 | Ser - Phe | NA | Gyeonggi Province in Korea |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone | 248 | C - A | 83 | Ser - Tyr | NA | Gyeonggi Province in Korea |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone (Levofloxacin) | 250 - 252 | NA | 84 | Ser - Arg | NA | Japan |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone (Levofloxacin) | 250 - 252 | NA | 84 | Ser - Ile | NA | Japan |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone (Levofloxacin) | 251 | C - A | 84 | Ser - Tyr | NA | Japan |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone | 260 | A - G | 87 | Glu - Gly | NA | Gyeonggi Province in Korea |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone (Levofloxacin) | 262 | G - C | 88 | Glu - Gln | NA | Japan |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone (Levofloxacin) | 263 | A - G | 88 | Glu - Gly | NA | Japan |
| Enterococcus faecium | gyrA | LK25_09795 | Fluoroquinolone (Levofloxacin) | 262 | G - A | 88 | Glu - Lys | NA | Japan |
| Morganella morganii | gyrA | LR61_04405 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 247 - 249 | NA | 83 | Ser - Arg | NA | Argentina |
| Morganella morganii | gyrA | LR61_04405 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | AGC - ATC | 83 | Ser - Ile | NA | Argentina |
| Salmonella enterica Serovar Paratyphi A | gyrA | LW89_00955 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | -4.56 | India |
| Salmonella enterica Serovar Paratyphi A | gyrA | LW89_00955 | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | India |
| Enterobacter cloacae | gyrA | MC57_23210 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | TCC - TTC | 83 | Ser - Phe | NA | Argentina |
| Enterobacter cloacae | gyrA | MC57_23210 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | TCC - TAC | 83 | Ser - Tyr | NA | Argentina |
| Enterobacter cloacae | gyrA | MC57_23210 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 260 | GAC - GCC | 87 | Asp - Ala | NA | Argentina |
| Enterobacter cloacae | gyrA | MC57_23210 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 259 | GAC - AAC | 87 | Asp - Asn | NA | Argentina |
| Enterobacter cloacae | gyrA | MC57_23210 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 260 | GAC - GGC | 87 | Asp - Gly | NA | Argentina |
| Proteus mirabilis | gyrA | MC72_10645 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 247 - 249 | NA | 83 | Ser - Arg | NA | Argentina |
| Proteus mirabilis | gyrA | MC72_10645 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | AGC - ATC | 83 | Ser - Ile | NA | Argentina |
| Proteus mirabilis | gyrA | MC72_10645 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 260 | A - G | 87 | Glu - Gly | NA | Argentina |
| Mycoplasma genitalium | gyrA | MG_004 | Fluoroquinolone | 259 | G - A | 87 | Asp - Asn | NA | Japan |
| Mycobacterium leprae | gyrA | ML0006 | Quinolone | 272 | GCA - GTA | 91 | Ala - Val | -2.41 | eastern Uttar Pradesh in India |
| Mycobacterium leprae | gyrA | ML0006 | Fluoroquinolone (Ofloxacin) | 272 | C - T | 91 | Ala - Val | -2.41 | NA |
| Mycobacterium leprae | gyrA | ML0006 | Quinolone | 271 | G - A | 91 | Ala - Thr | 0.163 | eastern Uttar Pradesh in India |
| Mycobacterium leprae | gyrA | ML0006 | Quinolone | 274 | T - G | 92 | Ser - Ala | 1.304 | eastern Uttar Pradesh in India |
| Staphylococcus pseudintermedius | gyrA | NO89_11120 | Fluoroquinolone | 251 | C - T | 84 | Ser - Leu | -4.988 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 569 | CCG - CTG | 190 | Pro - Leu | -9.946 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 262 | GGC - TGC | 88 | Gly - Cys | -8.938 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 262 | GGC - TGC | 88 | Gly - Cys | -8.938 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 281 | GAC - GTC | 94 | Asp - Val | -8.824 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - TAC | 94 | Asp - Tyr | -8.817 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 | GAC - TAC | 94 | Asp - Tyr | -8.817 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 280 | GAC - TAC | 94 | Asp - Tyr | -8.817 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - TAC | 94 | Asp - Tyr | -8.817 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 280 | GAC - TAC | 94 | Asp - Tyr | -8.817 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin / Ofloxacin / Sparfloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | Morocco |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 280 | GAC - CAC | 94 | Asp - His | -6.839 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 280 | GAC - CAC | 94 | Asp - His | -6.839 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - CAC | 94 | Asp - His | -6.839 | Morocco |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | United States |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 263 | GGC - GCC | 88 | Gly - Ala | -5.957 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | United States |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin / Ofloxacin / Sparfloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin / Ofloxacin / Sparfloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | Morocco |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 1151 | GCA - GTA | 384 | Ala - Val | -3.839 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 1151 | GCA - GTA | 384 | Ala - Val | -3.839 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | United States |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | Morocco |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | United States |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ciprofloxacin / Ofloxacin / Sparfloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | Morocco |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GGG | 90 | Ala - Gly | -1.566 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 394 | GCC - TCC | 132 | Ala - Ser | -0.917 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Moxifloxacin) | 394 | GCC - TCC | 132 | Ala - Ser | -0.917 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 268 | GCG - ACG | 90 | Ala - Thr | 0.354 | Morocco |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 284 | AGC - ACC | 95 | Ser - Thr | 0.509 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 284 | AGC - ACC | 95 | Ser - Thr | 0.509 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 284 | AGC - ACC | 95 | Ser - Thr | 0.509 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 284 | AGC - ACC | 95 | Ser - Thr | 0.509 | Italy and Abhkazia |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 305 | CCC - CAC | 102 | Pro - His | -6.203 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 284 | AGC - ACC | 95 | Ser - Thr | 0.509 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 | GAC - TAC | 94 | Asp - Tyr | -8.817 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 | GAC - CAC | 94 | Asp - His | -6.839 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GCC | 94 | Asp - Ala | -7.811 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 263 | GGC - GCC | 88 | Gly - Ala | -5.957 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 280 - 281 | GAC - GTC | 94 | Asp - Phe | -8.828 | Philippines |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 281 | GAC - GTC | 94 | Asp - Val | -8.824 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 263 | GGC - GCC | 88 | Gly - Ala | -5.957 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 265 | GAC - AAC | 89 | Asp - Asn | -4.968 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 325 | CTG - GTG | 109 | Leu - Val | -2.82 | India |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 269 | GCG - GGG | 90 | Ala - Gly | -1.566 | France |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 238 | ACC - GCC | 80 | Thr - Ala | -0.705 | France |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone | 220 | GCC - TCC | 74 | Ala - Ser | -0.438 | China |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | Thailand |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin / Moxifloxacin / Gatifloxacin / Levofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | Thailand |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin / Moxifloxacin / Gatifloxacin / Levofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | -6.78 | Thailand |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 265 | GAC - AAC | 89 | Asp - Asn | -4.968 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin / Levofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | Thailand |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin / Moxifloxacin / Levofloxacin) | 280 | GAC - AAC | 94 | Asp - Asn | -4.87 | Thailand |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 271 | TCG - CCG | 91 | Ser - Pro | -2.416 | NA |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | Taiwan |
| Mycobacterium tuberculosis | gyrA | Rv0006 | Fluoroquinolone (Ofloxacin) | 269 | GCG - GTG | 90 | Ala - Val | -2.409 | NA |
| Salmonella enterica Serovar Indiana | gyrA | SEEI1959_02253 | Fluoroquinolone (Ciprofloxacin) | 260 | A - G | 87 | Asp - Gly | -6.468 | NA |
| Salmonella enterica Serovar Indiana | gyrA | SEEI1959_02253 | Fluoroquinolone (Ciprofloxacin) | 248 | C - T | 83 | Ser - Phe | -4.548 | NA |
| Salmonella enterica Serovar Infantis | gyrA | SIN_02308 | Fluoroquinolone (Ciprofloxacin) | 259 | G - T | 87 | Asp - Tyr | -8.274 | United States |
| Klebsiella oxytoca | gyrA | SK88_04214 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | ACC - ATC | 83 | Thr - Ile | NA | Argentina |
| Salmonella enterica Serovar Kentucky | gyrA | TJ54_10510 | Quinolone | 248 | C - T | 83 | Ser - Phe | NA | Ethiopia |
| Salmonella enterica Serovar Kentucky | gyrA | TJ54_10510 | Quinolone | 248 | C - A | 83 | Ser - Tyr | NA | Ethiopia |
| Salmonella enterica Serovar Kentucky | gyrA | TJ54_10510 | Quinolone | 260 | A - G | 87 | Asp - Gly | NA | Ethiopia |
| Ureaplasma parvum | gyrA | UPA1_G0337 | Fluoroquinolone (Ciprofloxacin / Ofloxacin) | 232 - 234 | NA | 78 | Lys - Ile | -6.069 | Italy |
| Ureaplasma parvum | gyrA | UPA1_G0337 | Fluoroquinolone (Ciprofloxacin / Ofloxacin) | 201 | T - A | 67 | Phe - Ile | -3.836 | Italy |
| Ureaplasma parvum | gyrA | UPA1_G0337 | Fluoroquinolone (Ciprofloxacin / Ofloxacin) | 526 | C - T | 176 | Leu - Phe | -3.516 | Italy |
| Ureaplasma parvum | gyrA | UPA1_G0337 | Fluoroquinolone (Ciprofloxacin / Ofloxacin) | 520 - 522 | NA | 174 | Ser - Arg | -1.272 | Italy |
| Ureaplasma parvum | gyrA | UPA1_G0337 | Fluoroquinolone (Ciprofloxacin / Ofloxacin) | 535 - 537 | NA | 179 | Gly - Asp | -0.283 | Italy |
| Ureaplasma urealyticum | gyrA | UUR10_0088 | Fluoroquinolone (Ciprofloxacin / Ofloxacin) | 230 | A - T | 77 | Asp - Val | -6.877 | Italy |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 260 | NA | 87 | Asp - Ala | -7.171 | Argentina |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 260 | A - G | 87 | Asp - Gly | -6.368 | Argentina |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | C - A | 83 | Ser - Tyr | -4.623 | Argentina |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | C - T | 83 | Ser - Phe | -4.606 | Argentina |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Quinolone | 259 | G - A | 87 | Asp - Asn | -4.46 | West Bengal in India |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Quinolone | 248 | TCG - TTG | 83 | Ser - Leu | -4.3 | West Bengal in India |
| Klebsiella pneumoniae | gyrA | UUU_29370 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | AGC - ATC | 83 | Ser - Ile | -4.26 | Argentina |
| Campylobacter coli | gyrA | VC76_04995 | Fluoroquinolone (Enrofloxacin) | 257 | ACT - ATT | 86 | Thr - Ile | -3.687 | Thailand |
| Campylobacter coli | gyrA | VC76_04995 | Fluoroquinolone | 257 | ACT - ATT | 86 | Thr - Ile | -3.687 | United States |
| Campylobacter coli | gyrA | VC76_04995 | Fluoroquinolone | 257 | ACT - ATT | 86 | Thr - Ile | -3.687 | NA |
| Corynebacterium striatum | gyrA | WU85_09410 | Fluoroquinolone | 272 | A - C | 91 | Asp - Ala | -7.803 | Sousse in Tunisia |
| Corynebacterium striatum | gyrA | WU85_09410 | Fluoroquinolone | 272 | A - G | 91 | Asp - Gly | -6.768 | Sousse in Tunisia |
| Corynebacterium striatum | gyrA | WU85_09410 | Fluoroquinolone | 260 | C - A | 87 | Ser - Tyr | -4.524 | Sousse in Tunisia |
| Corynebacterium striatum | gyrA | WU85_09410 | Fluoroquinolone | 260 | C - T | 87 | Ser - Phe | -4.522 | Sousse in Tunisia |
| Corynebacterium striatum | gyrA | WU85_09410 | Fluoroquinolone | 259 | T - G | 87 | Ser - Ala | -1.338 | Sousse in Tunisia |
| Mycobacterium fortuitum | gyrA | XA26_00080 | Fluoroquinolone (Moxifloxacin) | 272 | TCG - TTG | 91 | Ser - Leu | -4.259 | China |
| Mycobacterium fortuitum | gyrA | XA26_00080 | Fluoroquinolone (Moxifloxacin) | 283 | AGC - GGC | 95 | Ser - Gly | NA | China |
| Mycobacterium fortuitum | gyrA | XA26_00080 | Fluoroquinolone (Moxifloxacin) | 284 | A - G | 95 | Asp - Gly | -6.768 | Guangzhou in China |
| Mycobacterium fortuitum | gyrA | XA26_00080 | Fluoroquinolone (Moxifloxacin) | 272 | C - T | 91 | Ser - Leu | -4.259 | Guangzhou in China |
| Salmonella sps. | gyrA | NA | Quinolone | 248 | C - A | 83 | Ser - Tyr | NA | NA |
| Salmonella sps. | gyrA | NA | Quinolone | 248 | C - T | 83 | Ser - Phe | NA | NA |
| Avian-pathogenic Escherichia coli | gyrA | NA | Fluoroquinolone (Ciprofloxacin) | 248 | TCG - TTG | 83 | Ser - Leu | NA | Egypt |
| Enterobacter aerogenes | gyrA | NA | Fluoroquinolone (Ciprofloxacin / Levofloxacin) / Nalidixic Acid | 248 | ACC - ATC | 83 | Thr - Ile | NA | Argentina |
| Shigella sps. | gyrA | NA | Quinolone | 247 | TCG - GCG | 83 | Ser - Ala | NA | Tehran in Iran |
| Shigella sps. | gyrA | NA | Quinolone | 248 | TCG - TTG | 83 | Ser - Leu | NA | Tehran in Iran |
| Campylobacter sps. | gyrA | NA | Nalidixic Acid / Fluoroquinolone (Ciprofloxacin) | 257 | C - T | 86 | Thr - Ile | NA | NA |
| Salmonella sps. | gyrA | NA | Quinolone | 259 | G - A | 87 | Asp - Asn | NA | NA |
| Avian-pathogenic Escherichia coli | gyrA | NA | Fluoroquinolone (Ciprofloxacin) | 259 | G - A | 87 | Asp - Asn | NA | Egypt |
| Shigella sps. | gyrA | NA | Quinolone | 260 | GAC - GGC | 87 | Asp - Gly | NA | Tehran in Iran |
| Shigella sps. | gyrA | NA | Quinolone | 259 | GAC - TAC | 87 | Asp - Tyr | NA | Tehran in Iran |
| Salmonella sps. | gyrA | NA | Quinolone | 1744 - 1746 | NA | 582 | Leu - Gly | NA | NA |
| Mycobacterium tuberculosis complex | gyrA | NA | Fluoroquinolone (Ofloxacin) | 281 | GAC - GCC | 94 | Asp - Ala | NA | Nigeria |
| Mycobacterium tuberculosis complex | gyrA | NA | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | NA | Nigeria |
| Mycobacterium tuberculosis complex | gyrA | NA | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | NA | Nigeria |
| Mycobacterium tuberculosis complex | gyrA | NA | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | NA | Nigeria |
| Mycobacterium tuberculosis complex | gyrA | NA | Fluoroquinolone (Ofloxacin) | 281 | GAC - GGC | 94 | Asp - Gly | NA | Nigeria |